KYMR
Kymera Therapeutics
$110.05
−$0.52 (−0.47%)Jul 27, 2026
Key metrics
The numbers that frame KYMR today
- Market cap
- $9.05B
- P/E (TTM)
- -28.7
- EV / FCF
- -36.8
- Gross margin
- 100%
- EV / Sales
- 174.5
- ROIC
- -26.8%
- Div yield
- 0%
- Debt / equity
- 0.1
- 52wk Low
- $36.65
- 52wk High
- $130.05
Growth
Revenue and earnings trend for KYMR
RevenueNet income
See the full growth breakdown
Revenue and earnings trends, margins and the multi-year trajectory - free with an account.
Create a free accountFree foreverNo card required
Already a member? Log inCash flow & returns
Free cash flow and financial health
Free cash flowNet debt
See the full cash-flow picture
Free cash flow detail, returns on capital and the balance-sheet trend - free with an account.
Create a free accountFree foreverNo card required
Already a member? Log inInsider trading
Recent insider buying and selling activity
PurchasesSales
Unlock every insider trade
See who is buying and selling, how much, and when - updated as new filings land.
Create a free accountFree foreverNo card required
Already a member? Log inFrequently asked questions
Plain-English answers about KYMR
Is Kymera Therapeutics a good buy?
Hold. Kymera Therapeutics has excellent momentum, but poor quality makes the setup mixed. Growth looks excellent, which supports the long-term business case. We think Kymera Therapeutics is selling at a high price.
What is the market capitalization of KYMR?
Kymera Therapeutics's market capitalization is $9.05B.
What is the P/E ratio for KYMR stock?
Kymera Therapeutics's current P/E ratio is -28.7.
What is the 52-week high for KYMR stock?
The 52-week high for Kymera Therapeutics is $130.05. The current close of $110.05 is 15.4% below that high.
What is the 52-week low for KYMR stock?
The 52-week low for Kymera Therapeutics is $36.65. The current close of $110.05 is 200.3% above that low.
Does KYMR stock pay dividends?
Kymera Therapeutics does not currently show a dividend per share in the company data.
What is the Debt / Equity ratio for KYMR?
Kymera Therapeutics's Debt / Equity ratio is 0.05.